Have a Topic Idea?

What would you like to see featured on MedConnect? Let us know.

Submit an Idea

Hurricane Florence Support

Hurricane Florence Support MedImpact Activates Natural Disaster Response and Provides Emergency Medication Tips As life-threatening Hurricane Florence forces mass...

Moving Toward Performance-Based Networks

Moving Toward Performance-Based Networks MedImpact Discusses Trends in Value-Based Pharmacy Reimbursement In a recent issue of Chain Drugstore Daily , Dave...

Don’t Get Lost in the Crowded Orphan Drug Market

Don’t Get Lost in the Crowded Orphan Drug Market MedImpact Offers Insight on Managing Blockbuster Drugs MedImpact Expects Orphan Drug Approval to Increase ...

Biosimilar News Tops Industry Headlines

MedImpact’s Annual Trend Report Spotlights Oncology. Oncology received more new FDA approvals in 2017 than any other therapeutic class — and this trend will likely continue through 2018 and...

Spotlight on Multiple Sclerosis

Spotlight on Multiple Sclerosis As MS drugs continue to make headlines, MedImpact’s Annual Trend Report offers insights on trends As the number of people suffering...

FDA Approves First Preventive Treatment for Migraine

FDA Approves First Preventive Treatment for Migraine The U.S. Food and Drug Administration (FDA) recently approved Aimovig (erenumab-aooe), the first preventive treatment...

MedImpact Achieves Low Medicare & Medicaid Trend

MedImpact Achieves Low Medicare & Medicaid Trend in Spite of CMS Reports of Skyrocketing Drug Costs The Centers for Medicare & Medicaid Services (CMS) released this...

MedImpact Holds 2016 Annual Trend to 2.9 Percent

MedImpact, an independent, trend-focused PBM, held its 2016 overall annual trend to a mere 2.9 percent. The MedImpact Annual Trend Report examined the annual trend by...

MedImpact Achieves Record-Low Trend

Commercial plans realize the lowest drug spend to date — with only a 1.6 percent increase MedImpact released its 2017 Annual Trend Report — reavealing record-low...

MedImpact Reduces Opioid Overutilization by 36 Percent

In an announcement released Nov. 8, MedImpact revealed the success of the MedImpact Overutilization and Safety Controls Program addressing opioid overutilization. A ...

Biosimilars: The Challenges and The Opportunities

Biosimilar drugs present a large potential for reducing specialty spending, but their instability and sensitivity to manufacturing present challenges as well. Biosimilars...

Examining Drug Trend: HIV

Drug price drove 2016 trend. Overall utilization for the top 10 therapeutic classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will...

Drug Information Update- Mavyret (glecaprevir/pibrentasvir)

Mavyret (glecaprevir/pibrentasvir) New Drug Approval: On August 3, 2017 the FDA approved Mavyret for the treatment of adult patients with chronic...

National Drug Take Back Day Yields 450 TONS of Unused Medications

Rise in Prescription Waste is Costing Unnecessary Money Saturday, April 29 was Drug Take Back Day, where unused drugs were returned in droves to designated Drug...

Examining Drug Trend: Hepatitis C

Top 10 Classes - What is Driving Drug Trend Drug price is driving trend. Overall utilization for the top 10 therapeutic classes in 2016 decreased, while prices...

Examining Drug Trend: Oncology

Top 10 Classes - What is Driving Drug Trend Drug price is driving trend. Overall utilization for the top 10 drug classes in 2016 decreased, while prices increased....